Navidea Biopharmaceuticals, Inc.

NAVB

US63937X2027

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:15:48 20/05/2024 pm IST			5-day change	1st Jan Change
0.03 ^USD	+15.38%		+20.00%	-45.65%

2023	Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding	CI
2023	Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin, as Chief Financial Officer

October 27, 2021 at 02:52 am IST

Navidea Biopharmaceuticals, Inc. announced the resignation of Jed A. Latkin as Chief Financial Officer of the Company, effective October 24, 2021.

Latest news about Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding	27/11	CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Navidea Biopharmaceuticals, Inc.(OTCPK:NAVB) dropped from S&P TMI Index	11/23/11	CI
Sector Update: Health Care	07/23/07	MT
Top Midday Decliners	07/23/07	MT
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision	06/23/06	MT
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
Navidea Biopharmaceuticals, Inc. Announces Resignation of Malcolm G. Witter as Director, Member of the Audit Committee and Compensation, Nominating and Governance Committee of the Board	09/23/09	CI
Navidea Biopharmaceuticals, Inc. Announces Executive Changes	29/23/29	CI
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer	28/23/28	CI
Navidea Biopharmaceuticals, Inc. Announces Board Changes	14/23/14	CI
Navidea Biopharmaceuticals Confirms Rejection of ProPhase Labs' Proposal to Buy Some of Its Assets	30/23/30	MT
ProPhase Labs Says Offer to Acquire Certain Navidea Biopharmaceuticals' Assets Rejected	29/23/29	MT
ProPhase Labs, Inc. cancelled the acquisition of Certain Assets from Navidea Biopharmaceuticals, Inc. for $7 million.	29/23/29	CI
Sector Update: Health Care Stocks Steady Late Friday	17/23/17	MT
Sector Update: Health Care	17/23/17	MT
Navidea Biopharmaceuticals Gets $7.5 Million Payment From Cardinal Health	17/23/17	MT
Navidea Biopharmaceuticals Notified of Non-Compliance With NYSE American Listing Rule	05/23/05	MT
Navidea Biopharmaceuticals, Inc. Announces Board Changes	02/23/02	CI
Navidea Biopharmaceuticals Sells Preferred Shares Worth $1.1 Million	23/23/23	MT
Navidea Biopharmaceuticals, Inc. announced that it expects to receive $1.1 million in funding	22/23/22	CI
Navidea Biopharmaceuticals Promotes Michael Sherman Blue to Chief Medical Officer	12/23/12	MT
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer	12/23/12	CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Navidea Biopharmaceuticals Intends to Sell Cardinal Milestone Payment	28/23/28	CI

Chart Navidea Biopharmaceuticals, Inc.

Duration

Period

More charts

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Companyâs business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NAVIDEA BIOPHARMACEUTICALS, INC.	-45.65%	3M
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+44.36%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B